A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Amivantamab (JNJ61186372), a Human Bispecific EGFR and cMet Antibody, in Participants with Advanced Non-Small Cell Lung Cancer

2023-509435-11-00 Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 21 Feb 2019 · Status Ongoing, recruitment ended · 2 EU/EEA countries · 7 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 660
Countries 2
Sites 7

Advanced Non-Small Cell Lung Cancer

Key facts

Sponsor
Janssen Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
21 Feb 2019 → ongoing
Decision date (initial)
2024-04-29
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-509435-11-00
EudraCT number
2018-003908-38

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Non-Small Cell Lung Cancer

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

2 EU/EEA countries · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 7 6
Italy Ongoing, recruitment ended 1 1
Rest of world
United States, Canada, Australia, China, Korea, Republic of, United Kingdom, Japan, Taiwan
652

Investigational sites

France

6 sites · Ongoing, recruitment ended
Institut Curie
Thoracic oncology, 26 Rue D Ulm, 75005, Paris
Assistance Publique Hopitaux De Marseille
ONCOLOGY AND THERAPEUTIC INNOVATIONS, 265 Chemin Des Bourrely, 13015, Marseille
Centr Georges Francois Leclerc
MEDICAL ONCOLOGY, 1 Rue Professeur Marion, 21000, Dijon
Institut De Cancerologie De L Ouest
Oncology, Bd Du Professeur Jacques Monod, 44800, St Herblain
Institut Gustave Roussy
MEDICAL ONCOLOGY, 114 Rue Edouard Vaillant, 94800, Villejuif
Centre Leon Berard
MEDICAL ONCOLOGY, 28 Rue Laennec, 69008, Lyon

Italy

1 site · Ongoing, recruitment ended
Fondazione IRCCS Istituto Nazionale Dei Tumori
S.S. Oncologia Medica Toraco-Polmonare, Via Giacomo Venezian 1, 20133, Milan

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2019-02-21 2019-02-21 2022-12-22
Italy 2020-06-03 2020-06-03 2022-11-03

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-09 France Acceptable
2024-04-29
2024-04-29
2 SUBSTANTIAL MODIFICATION SM-1 2024-08-29 France Acceptable
2024-10-09
2024-10-15
3 SUBSTANTIAL MODIFICATION SM-2 2025-08-14 France Acceptable
2025-10-27
2025-10-27
4 SUBSTANTIAL MODIFICATION SM-3 2025-12-08 France Acceptable
2026-01-28
2026-01-28